Evolving issues in understanding and treating bacterial vaginosis

Expert Review of Anti-Infective Therapy

Volumn 2, Issue 6, 2004, Pages 913-922

  Marrazzo, Jeanne M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Bacterial vaginosis; Lactobacillus spp.; Sexually transmitted diseases; Vaginitis

Indexed keywords

ACIJEL; AMINOTRANSFERASE; CARBOPOL 974P; CLINDAMYCIN; HYDROGEN PEROXIDE; METRONIDAZOLE; NONOXINOL 9; PROBIOTIC AGENT; SPERMICIDAL AGENT; TINIDAZOLE; UNCLASSIFIED DRUG; YOGHURT;

ABDOMINAL CRAMP; BACTERIAL COUNT; BACTERIUM DETECTION; CLOSTRIDIUM DIFFICILE; COMMENSALISM; CONDOM; CONFUSION; DIARRHEA; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; EXPERIENCE; FEMALE; GARDNERELLA VAGINALIS; GRAM POSITIVE BACTERIUM; GRAM STAINING; GYNECOLOGIC SURGERY; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTOBACILLUS; LIVER DYSFUNCTION; LOW BIRTH WEIGHT; MOBILUNCUS; MYCOPLASMA HOMINIS; NAUSEA AND VOMITING; NEUTROPENIA; PATIENT COUNSELING; PELVIC INFLAMMATORY DISEASE; PERSONAL HYGIENE; PH; POSTOPERATIVE INFECTION; PREGNANCY; PREMATURE LABOR; PREVOTELLA; RECURRENT INFECTION; REVIEW; RISK ASSESSMENT; SEIZURE; SEXUAL BEHAVIOR; SEXUAL TRANSMISSION; SPECIES IDENTIFICATION; SYMPTOM; TAMPON; TASTE DISORDER; TREATMENT OUTCOME; VAGINA DISCHARGE; VAGINA DISEASE; VAGINA FLORA; VAGINITIS;

EID: 9944253212     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14789072.2.6.913     Document Type: Review

References (111)

1. Hillier S. Normal vaginal flora. In: Sexually Transmitted Diseases, Third Edition. Holmes KK, Sparling PF, Mardh PA et al (Eds). McGraw-Hill, NY, USA, 191-201 (1999).
2. Brabin L. Interactions of the female hormonal environment, susceptibility to viral infections, and disease progression. AIDS Patient Care STDs 15, 211-221 (2002).
3. Sobel J. Current concepts: vaginitis. N. Engl. J. Med. 337, 1896-1903 (1997).
4. Klebanoff MA, Schwebke JR, Zhang J, Nansel TR, Yu KF, Andrews WW. Vulvovaginal symptoms in women with bacterial vaginosis. Obstet. Gynecol., 104, 267-272 (2004).
5. Olmsted SS, Meyn LA, Rohan LC, Hillier SL. Glycosidase and proteinase activity of anaerobic Gram-negative bacteria isolated from women with bacterial vaginosis. Sex Transmis. Dis. 30, 257-261 (2003).
6. Amsel R, Totten PA. Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am. J. Med. 74, 14-22 (1983).
7. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. J. Clin. Microbiol. 29, 297-301 (1991).
8. Myziuk L, Romanowski B, Johnson SC. BVBlue test for diagnosis of bacterial vaginosis. J. Clin. Microbiol. 41, 1925-1928 (2003).
9. Ferris DG, Litaker MS, Woodward L, Mathis D, Hendrich J. Treatment of bacterial vaginosis: a comparison of oral metronidazole, metronidazole vaginal gel, and clindamycin vaginal cream. J. Fam. Pract. 41, 443-449 (1995).
10. Ferris DG, Nyirjesy P, Sobel J, Soper DE, Pavletic A, Litaker MS. Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. Obstet. Gynecol. 99, 419-425 (2002).
11. Hillier S, Holmes KK. Bacterial vaginosis. In: Sexually Transmitted Diseases, Third Edition. Holmes KK, Sparling PF, Mardh PA et al (Eds). McGraw-Hill, NY, USA, 563-586 (1999).
12. Ferris MJ, Masztal A, Aldridge KE, Fortenberry JD, Fidel PL Jr, Martin DH. Association of Atopobium vaginae, a recently described metronidazole resistant anaerobe, with bacterial vaginosis. BMC Infect. Dis. 4, 5 (2004).
13. Hawes SE, Hillier SL, Benedetti J et al. Hydrogen peroxide-producing lactobacilli and acquisition of vaginal infections. J. Infect. Dis. 174, 1058-1063 (1996).
14. Barbone F, Austin H, Louv WC, Alexander WJ. A follow-up study of methods of contraception, sexual activity, and rates of trichomoniasis, candidiasis, and bacterial vaginosis. Am. J. Obstet. Gynecol. 163, 510-514 (1990).
15. Avonts D, Sercu M, Heyerick P, Vandermeeren I, Meheus A, Piot P. Incidence of uncomplicated genital infections in women using oral contraception or an intrauterine device: a prospective study. Sex Transmis. Dis. 17, 23-29 (1990).
16. Schwebke JR, Richey CM, Weiss HL. Correlation of behaviors with microbiological changes in vaginal flora. J. Infect. Dis. 180, 1632-1636 (1999).
17. Tchamouroff SE, Panja SK. The association between receptive cunnilingus and bacterial vaginosis. Sex. Transmis. Infect. 76, 144-145 (2000).
18. Ison CA, Easmon CS. Carriage of Gardnerella vaginalis and anaerobes in semen. Genitourin. Med. 60, 120 (1985).
19. Holst E. Reservoir of four organisms associated with bacterial vaginosis suggests lack of sexual transmission. J. Clin. Microbiol. 28, 2035-2039 (1990).
20. Moi H, Erkkola R, Jerve F et al. Should male consorts of women with bacterial vaginosis be treated? Genitourin. Med. 65, 263-268 (1989).
21. Lugo-Miro VI, Green M, Mazur L. Comparison ofdiflerent metronidazole therapeutic regimens fbr bacterial vaginosis. A meta-analysis. J. Am. Med. Assoc. 268, 92-95 (1992).
22. Vejtorp M, Bollerup AC, Vejtorp L et al. Bacterial vaginosis: a double-blind randomized trial of the effect of treatment of the sexual partner. Br. J. Obstet. Gynaecol. 95, 920-926 (1988).
23. Swedberg J, Steiner JF, Deiss F, Steiner S, Driggers DA. Comparison of single-dose vs. 1-week course of metronidazole for symptomatic bacterial vaginosis. J. Am. Med. Assoc. 254, 1046-1049 (1985).
24. Colli E, Landoni M, Parazzini F. Treatment of male partners and recurrence of bacterial vaginosis: a randomized trial. Genitourin. Med. 73, 267-270 (1997).
25. Hamrick M, Chambliss ML. Bacterial vaginosis and treatment of sexual partners. Arch. Fam. Med. 9, 647-648 (2000).
26. Mengel MB, Berg AO, Weaver CH et al. The effectiveness of single-dose metronidazole therapy for patients and their partners with bacterial vaginosis. J. Fam. Pract. 28, 163-171 (1989).
27. Bump RC, Buesching WJ 3rd. Bacterial vaginosis in virginal and sexually active adolescent females: evidence against exclusive sexual transmission. Am. J. Obstet. Gynecol. 158, 935-939 (1988).
28. Calzolari E, Masciangelo R, Milite V, Verteramo R. Bacterial vaginosis and contraceptive methods. Int. J. Gynaecol. Obstet. 70, 341-346 (2000).
29. Shoubnikova M, Hellberg D, Nilsson S, Mardh PA. Contraceptive use in women with bacterial vaginosis. Contraception 55, 355-358 (1997).
30. Royce RA, Jackson TP, Thorp JM Jr et al. Race/ethnicity, vaginal flora patterns, and pH during pregnancy. Sex Transmis. Dis. 26, 96-402 (1999).
31. Culhane JF. Rauh V, McCollum KF, Elo IT, Hogan V. Exposure to chronic stress and ethnic differences in rates of bacterial vaginosis among pregnant women. Am. J. Obstet. Gynecol. 187, 1272-1276 (2002).
32. Berger BJ, Kohon S, Zenilman JM, Cummings MC, Feldman J, McCormack WM. Bacterial vaginosis in lesbians: a sexually transmitted disease. Clin. Infect. Dis. 21, 1402-1405 (1995).
33. Skinner CJ, Stokes J, Kirlew Y, Kavanagh J, Forster GE. A case-controlled study of the sexual health needs of lesbians. Genitourin. Med. 72, 277-280 (1996).
34. Fethers K, Marks C, Mindel A. Estcourt CS. Sexually transmitted infections and risk behaviours in women who have sex with women. Sex. Transmis. Infect. 76, 345-349 (2000).
35. Edwards ATR. Sexually transmitted diseases in lesbians. Int. J. STD AIDS 1, 178-181 (1990).
36. Evans BA, Kell PD, Bond RA, MacRae KD. Racial origin, sexual lifestyle, and genital infection among women attending a genitourinary medicine clink in London. Sex. Transmis. Infect. 74, 45-49 (1992).
37. McCaffrey M, Varney P, Evans B, Taylor-Robinson D. Bacterial vaginosis in lesbians: evidence for lack of sexual transmission. Int. J. STD AIDS 10, 305-308 (1999).
38. Marrazzo JM, Koutsky LA, Eschenbach DA, Agnew K, Stine K, Hillier SL. Characterization of vaginal flora and bacterial vaginosis in women who have sex with women. J. Infect. Dis. 185, 1307-1313 (2002).
39. Criswell BS, Ladwig CL, Gardner HL, Dukes CD. Haemophilus vaginalis: vaginitis by inoculation from culture. Obstet. Gynecol. 33, 195-199 (1969).
40. Kilic AO, Pavlova SI, Alpay S, Kilic SS, Tao L. Comparative study of vaginal Lactabacillus phages isolated from women in the United States and Turkey: prevalence, morphology, host range, and DNA homology. Clin. Diagn. Lab. Immunol. 8, 31-39 (2001).
41. Baeten JM, Nyange PM, Richardson BA et al. Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study. Am. J. Obstet. Gynecol. 185, 380-385 (2001).
42. Smart S, Singal A, Mindel A. Social and sexual risk factors for bacterial vaginosis. Sex. Thansmis. Infect. 80, 58-62 (2004).
43. Hillier SL, Nugent RP, Eschenbach DA et al. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. The Vaginal Infections and Prematurity Study Group. N. Engl. J. Med. 333, 1737-1742 (1995).
44. Meis PJ, Goldenberg RL. Mercer B et al. The preterm prediction study: significance of vaginal infections. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am. J. Obstet. Gynecol. 173, 1231-1235 (1995).
45. Hillier SL, Kiviat NB, Hawes SE et al. Role of bacterial vaginosis-associated microorganisms in endometritis. Am. J. Obstet. Gynecol. 175, 435-441 (1996).
46. Goldenberg RL, Thom E, Moawad AH, Johnson F, Roberts J, Caritis SN. The preterm prediction study: fetal fibronectin, bacterial vaginosis, and peripartum infection. NICHD Maternal-Fetal Medicine Units Network. Obstet. Gynecol. 87, 656-660 (1996).
47. Ralph SG, Rutherford AJ, Wilson JD. Influence of bacterial vaginosis on conception and miscarriage in the first trimester: cohort study. Br. Med. J. 1319, 220-223 (1999).
48. Silver HM, Sperling RS, St Clair PJ, Gibbs RS. Evidence relating bacterial vaginosis to intraamniotic infection. Am. J. Obstet. Gynecol. 161, 808-812 (1989).
49. Hillier SL, Martius J, Krohn M, Kiviat N, Holmes KK, Eschenbach DA. A case-control study of chorioamnionitis infection and histologic chorioamnionitis in prematurity. N. Engl. J. Med. 319, 972-978 (1988).
50. Watts DH, Krohn MA, Hillier SL, Eschenbach DA. Bacterial vaginosis as a risk factor for postcesarean endometritis. Obstet. Gynecol. 75, 52-58 (1990).
51. Larsson PG, Platz-Christensen JJ, Thejls H, Forsum U, Pahison C. Incidence of pelvic inflammatory disease after first-trimester legal abortion in women with bacterial vaginosis after treatment with metronidazole: a double-blind, randomized study. Am. J. Obstet. Gynecol. 166, 100-103 (1992).
52. Sweet RL. Gynecologic conditions and bacterial vaginosis: implications for the nonpregnant patient. Infect. Dis. Obstet. Gynecol. 8, 184-190 (2000).
53. Larsson PG, Platz-Christensen JJ, Sundstrom E. Is bacterial vaginosis a sexually transmitted disease? Int. J. STD AIDS 2, 362-364 (1991).
54. Soper DE, Bump RC, Hurt WG. Bacterial vaginosis and trichomoniasis vaginitis are risk factors for cuff cellulitis after abdominal hysterectomy. Am. J. Obstet. Gynecol. 163, 1016-1021 (1990).
55. Wiesenfeld H, Hillier S, Krohn M et al. Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease. Obstet. Gynecol. 100, 456-463 (2002).
56. Martin HL, Richardson BA, Nyange PM et al. Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus Type 1 and sexually transmitted disease acquisition. J. Infect. Dis. 180, 1863-1868 (1999).
57. Wiesenfield HC, Hillier SL, Krohn MA. Landers DV, Sweet RL. Bacterial vaginosis is a strong predictor of Neisseria gonorrhoeae and Chlamydia trachomatis infection. Clin. Infect. Dis. 36, 663-668 (2003).
58. Schwebke JR, Schulien MB, Zajackowski M. Pilot study to evaluate the appropriate management of patients with coexistent bacterial vaginosis and cervicitis. Infect. Dis. Obstet. Gynecol. 3, 199-122 (1995).
59. Schwebke JR, Weiss HL. Interrelationships of bacterial vaginosis and cervical inflammation. Sex Transmis. Dis. 29, 59-64 (2002).
60. Miller L, Thomas K, Hughes JP, Holmes KK, Stout S, Eschenbach DA. Randomized treatment trial of bacterial vaginosis to prevent postabortion complication. Br. J. Obs. Gynecol. 111, 982-988 (2004).
61. Cu-Uvin S, Hogan JW, Caliendo AM, Harwell J, Mayer KH, Carpenter CC. Association between bacterial vaginosis and expression of human immunodeficiency virus Type 1 RNA in the female genital tract. Clin. Infect. Dis. 33, 894-896 (2001).
62. Seck K, Samb N, Tempesta S et al. Prevalence and risk factors of cervicovaginal HIV shedding among HIV-1 and HIV-2 infected women in Dakar, Senegal. Sex. Transmis. Infect. 77, 190-193 (2001 ).
63. Schmid G, Markowitz L, Joesoef R, Koumans E. Bacterial vaginosis and HIV infection. Sex. Transmis. Infect. 76, 3-4 (2000 ).
64. Taha TE, Hoover DR, Dallabetta GA et al. Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. AIDS 12, 1699-706 (1998).
65. Wawer MJ, Sewankambo NK, Serwadda D et al. Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomized community trial. Rakai Project Study Group. Lancet 353, 525-535 (1999).
66. Hashemi FB, Ghassemi M, Faro S. Aroutcheva A, Spear GT. Induction of human immunodeficiency virus Type 1 expression by anaerobes associated with bacterial vaginosis. J. Infect. Dis. 181, 1574-1580 (2000).
67. Al-Harthi L., Roebuck KA, Olinger GG et al. Bacterial vaginosis-associated microflora isolated from the female genital tract activates HIV-1 expression. J. Acquir. Immune. Defic. Syndr. 21, 194-202 (1999).
68. Olinger GG, Hashemi FB, Sha BE, Spear GT. Association of indicators of bacterial vaginosis with a female genital tract factor that induces expression of HIV-1. AIDS 13, 1905-1912 (1999).
69. Draper D, Landers D, Krohn M, Hillier S, Wiesenfeld H, Heine R. Levels of vaginal secretory leukocyte protease inhibitor are decreased in women with lower reproductive tract infections. Am. J. Obstet. Gynecol. 183, 1243-1248 (2000).
70. Yudin MH, Landers DV, Meyn L, Hillier SL. Clinical and cervical cytokine response to treatment with oral or vaginal metronidazole for bacterial vaginosis during pregnancy: a randomized trial. Obstet. Gynecol. 102, 527-534 (2003).
71. Sewankambo N, Gray RH, Wawer MJ et al. HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis. Lancet 350, 546-550 (1997).
72. Goldenberg R, Hauth JC, Andrews WW. Intrauterine infection and preterm delivery. N. Engl. J. Med. 342, 1500-1547 (2000).
73. Balu RB, Savitz DA, Ananth CV et al. Bacterial vaginosis, vaginal fluid neutrophil defensins, and preterm birth. Obstet. Gynecol. 101, 862-868 (2003).
74. Koumans EH, Markowitz LE, Hogan V. Indications for therapy and treatment recommendations for bacterial vaginosis in nonpregnant and pregnant women: a synthesis of data. Clin. Infect. Dis. 35, S152-S172 (2002).
75. Centers for Disease Control and Prevention. Sexually transmitted disease treatment guidelines 2002. Morb. Mortal. Wkly Rep. 51 (RR-6), 1-80 (2002).
76. Hanson JM, McGregor JA, Hillier SL et al. Metronidazole for bacterial vaginosis. A comparison of vaginal gel vs. oral therapy. J. Reprod. Med. 45, 889-896 (2000).
77. Livengood CH 3rd, Soper DE, Sheehan KL et al. Comparison of once-daily and twice-daily dosing of 0.75% metronidazole gel in the treatment of bacterial vaginosis. Sex. Transmis. Dis. 26, 137-142 (1999).
78. Paavonen J, Mangioni C, Martin MA, Wajszczuk CP. Vaginal clindamycin and oral metronidazole for bacterial vaginosis: a randomized trial. Obstet. Gynecol., 96, 256-260 (2000).
79. Brocklehurst P, Hannah M, McDonald H. Interventions for treating bacterial vaginosis in pregnancy. Cochrane Database Syst. Rev. 2 (2000).
80. McCormack WM, Covino. JM, Thomason JL et al. Comparison of clindamycin phosphate vaginal cream with triple sulfonamide vaginal cream in the treatment of bacterial vaginosis. Sex Transmis. Dis. 28(10), 569-575 (2001).
81. Hillier SL, Lipinski C, Briselden AM, Eschenbach DA. Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis. Obstet. Gynecol. 81, 963-967 (1993).
82. Livengood CH 3rd, McGregor JA, Soper DE, Newton E, Thomason JL. Bacterial vaginosis: efficacy and safety of intravaginal metronidazole treatment. Am. J. Obstet. Gynecol. 170, 759-764 (1994).
83. Sobel JD, Schmitt C, Meriwether C. Long-term follow-up of patients with bacterial vaginosis treated with oral metronidazole and topical clindamycin. J. Infect. Dis. 167, 783-784 (1993).
84. Boris J, Påhlson C, Larsson P-G. 6 years observation after succesfid treatment of bacterial vaginosis. Infect. Dis. Obstet. Gynecol. 5(4), 297-302 (1997).
85. Eschenbach DA. History and review of bacterial vaginosis. Am. J. Obstet. Gynecol. 169, 441-445 (1993).
86. Sobel J. A randomized, placebo-controlled trial of metronidazole gel for suppression of recurrent BV. Presented at Annual Scientific Meeting and Symposium of the Infectious Disease Society for Obstetrics and Gynecology. San Diego, CA, USA. 5-7 August 2004.
87. Leitich H, Brunbauer M, Bodner-Adler B, Kaider A, Egarter C, Husslein P. Antibiotic treatment of bacterial vaginosis in pregnancy: a meta-analysis. Am. J. Obstet. Gynecol. 188, 752-758 (2003).
88. Kiss H, Petricevic L, Husslein P. Prospective randomized controlled trial of an infection-screening programme to reduce the rate of preterm delivery. Br. Med. J. 329, 371 (2004).
89. McDonald H, Brocklehurst P, Parsons J, Vigneswaran R. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst. Rev. 2, CD000262 (2003).
90. Guise J, Mahon SM, Aickin M, Helfand M, Peipert JF, Westhoff C. Screening for bacterial vaginosis in pregnancy. Am. J. Prev. Med. 20, 62-72 (2001).
91. ACOG committee opinion. Bacterial vaginosis screening for prevention of preterm delivery. Number 198, February 1998. Committee on Obstetric Practice. American College of Obstetricians and Gynecologists. Int. J. Gynaecol. Obstet. 61, 311-312 (1998).
92. Sobel JD, Nyirjesy P, Brown W. Tinidazole therapy for metronidazole-resistant vaginal trichomoniasis. Clin. Infect. Dis. 33, 1341-1346 (2001).
93. Hager WD. Treatment of metronidazole-resistant Trichomonas vaginalis with tinidazole: case reports of three patients. Sex. Transmis. Dis. 31, 343-345 (2004).
94. Milani M, Barcellona E, Agnello A. Efficacy of the combination of 2 g oral tinidazole and acidic buffering vaginal gel in comparison with vaginal clindamycin alone in bacterial vaginosis: a randomized, investigator-blinded, controlled trial. Eur. J. Obstet. Gynecol. Reprod. Biol. 109, 67-71 (2003).
95. Hughes VL, Hillier SL. Microbiologic characteristics of Lactobacillus products used for colonization of the vagina. Obstet. Gynecol. 75, 244-248 (1990).
96. Richardson BA, Lavreys; L, Martin HL Jr et al. Evaluation of a low-dose nonoxynol-9 gel for the prevention of sexually transmitted diseases: a randomized clinical trial. Sex. Transmis. Dis. 28, 394-400 (2001).
97. van De Wijgert J, Fullem A, Kelly C et al. Phase 1 trial of the topical microbicide BufferGel: safety results from four international sites. J. Acquir. Immune. Defic. Syndr. 26(1), 21-27 (2001).
98. Harwell JI, Moench T, Mayer KH, Chapman S, Rodriguez I, Cu-Uvin S. A pilot study of treatment of bacterial vaginosis with a buffering vaginal microbicide. J. Womens Health (Larchmt) 12, 255-259 (2003).
99. Holley RL, Richter HE, Varner RE, Pair L, Schwebke JR. A randomized, double-blind clinical trial of vaginal acidification versus placebo for the treatment of symptomatic bacterial vaginosis. Sex. Transmis. Dis. 31, 236-238 (2004).
100. Brzezinski A, Stern T, Arbel R, Rahav G, Benita S. Efficacy of a novel pH-buffering tampon in preserving the acidic vaginal PH during menstruation. Int. J. Gynaecol. Obstet. 85, 298-300 (2004).
101. Chaithongwongwatthana S, Limpongsanurak S, Sitthi-Amorn C. Single hydrogen peroxide vaginal douching versus single-dose oral metronidazole for the treatment of bacterial vaginosis: a randomized controlled trial. J. Med. Assoc. Thai 86(Suppl. 2), S379-S384 (2003).
102. Schrezenmeir J, de Vrese M. Probiotics, prebiotics, and synbiotics-approaching a definition. Am. J. Clin. Nutr. 73, S361-S364 (2001).
103. Reid G, Bocking A. The potential for probiotics to prevent bacterial vaginosis and preterm labor. Am. J. Obstet. Gynecol. 189, 1202-1208 (2003).
104. Antonio NLA, Hillier SL. DNA fingerprinting of Lactobacillus crispatus strain CTV-05 by repetitive element sequence-based PCR analysis in a pilot study of vaginal colonization. J. Clin. Microbiol. 41, 1881-1887 (2003).
105. Patton DL, Cosgrove Sweeney YT, Antonio MA, Rabe LK, Hillier SL. Lactobacillus crispatus capsules: single-use safety study in the Macaca nemestrina model. Sex. Transmis. Dis. 30, 568-570 (2003).
106. Martino JL, Vermund SH. Vaginal douching: evidence for risks or benefits to women's health. Epidemiol.Rev. 24, 109-124 (2002).
107. Marrazzo JM, Coffey P, Bingham A. Sexual practices, risk perception, and knowledge of bacterial vaginosis among lesbians. Presented at 2004 National STD Prevention Conference. Philadelphia, PA, USA, 8-11 March 2004.
108. Chang TL, Chang CH, Simpson DA et al. Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Proc. Natl Acad. Sci. USA 100, 11672-11677(2003).
109. Kekki M, Kurki T, Pelkonen J, Kurkinen-Raty M, Cacciatore B, Paavonen J. Vaginal clindamycin in preventing preterm birth and peripartal infections in asymptomatic women with bacterial vaginosis: a randomized, controlled trial. Obstet. Gynecol. 97, 643-648 (2001).
110. Kurkinen-Raty M, Vuopala S, Koskela M et al. A randomized controlled trial of vaginal clindamycin for early pregnancy bacterial vaginosis. Br. J. Obs. Gynecol. 107, 1427-1432 (2000).
111. Broumas AG, Basara LA. Potential patient preference for 3-day treatment of bacterial vaginosis: responses to new suppository form of clindamycin. Adv. Ther. 17, 159-166 (2000).